8-KMaterial AgreementsOther EventsExhibits & Filings

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Jun 8, 2005)

Filed June 8, 2005For Securities:VRTX

Summary

Vertex Pharmaceuticals Incorporated (VRTX) announced on June 7, 2005, the pricing of a public offering of its common stock. The company entered into a purchase agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated, acting as the representative for the underwriters, for the sale of 11,750,000 shares of common stock at an offering price of $13.00 per share. This offering aims to raise capital for the company, the specific use of which is not detailed in this filing but is typical for public stock offerings. Additionally, the agreement includes an over-allotment option for the underwriters to purchase up to an additional 1,762,500 shares within 30 days. This suggests underwriters' confidence in the offering and potential demand for Vertex's stock. Investors should note that this is a dilutive event, as new shares are being issued, which could impact earnings per share if not offset by significant growth.

Key Highlights

  • 1Vertex Pharmaceuticals announced a public offering of 11,750,000 shares of common stock.
  • 2The offering price was set at $13.00 per share.
  • 3Merrill Lynch, Pierce, Fenner & Smith Incorporated acted as the representative of the underwriters.
  • 4The company granted an over-allotment option to purchase up to an additional 1,762,500 shares.
  • 5This option is exercisable for 30 days.
  • 6The material definitive agreement is the Purchase Agreement dated June 7, 2005.
  • 7A press release announcing the pricing of the offering was issued on June 7, 2005.

Frequently Asked Questions

This 8-K filing announces Vertex Pharmaceuticals' entry into a material definitive agreement for a public offering of its common stock and provides related details, including the offering price and the involvement of underwriters.

Vertex Pharmaceuticals is selling 11,750,000 shares at $13.00 per share, which would generate gross proceeds of approximately $152.75 million before underwriting discounts and expenses. The potential for an additional 1,762,500 shares could increase gross proceeds by approximately $22.9 million if fully exercised.

The over-allotment option allows the underwriters to purchase up to an additional 1,762,500 shares of common stock from Vertex at the offering price. This option is typically granted to cover potential excess demand for the shares during the offering and suggests that the underwriters believe the stock may trade above the offering price after its release.

Yes, the issuance of 11,750,000 new shares will increase the total number of Vertex Pharmaceuticals' outstanding common shares. If the over-allotment option is exercised, the number of outstanding shares will increase further. This is known as dilution and can impact metrics like earnings per share.